Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12444727 | 0.85 | — | — | |
| SCHEMBL1818086 | 0.79 | MLYCD (0.42) | MLYCD | |
| SCHEMBL25691634 | 0.79 | MLYCD (0.31) | MLYCD | |
| SCHEMBL63072 | 0.79 | MLYCD (0.31) | MLYCD | |
| SCHEMBL29684122 | 0.79 | NOTUM (0.43) | MLYCDMEN1KMT2ATDP1PKM | |
| SCHEMBL23930073 | 0.79 | MLYCD (0.38) | MLYCD | |
| SCHEMBL2278324 | 0.79 | MLYCD (0.31) | MLYCD | |
| SCHEMBL1161728 | 0.76 | MLYCD (0.39) | MLYCDMEN1KMT2ATDP1PKM | |
| SCHEMBL28976107 | 0.76 | L3MBTL1 (0.37) | MLYCDMEN1KMT2ATDP1PKM | |
| SCHEMBL1538117 | 0.75 | RIPK1 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12583878-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2026-03-24 | — | — | US | disclosed |
| US-12460128-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2025-11-04 | — | — | US | disclosed |
| US-20250333421-A1 | PYRIDAZINES OR 1,2,4-TRIAZINES SUBSTITUTED BY SPIROCYCLIC AMINES | JANSSEN PHARMACEUTICA NV (BE) | 2025-10-30 | — | — | US | disclosed |
| US-20240066027-A1 | NOVEL PAR-2 INHIBITORS | DOMAIN THERAPEUTICS (FR) | 2024-02-29 | — | — | US | disclosed |
| EP-4255904-A2 | NOVEL PAR-2 INHIBITORS | Domain Therapeutics (FR) | 2023-10-11 | — | — | EP | disclosed |
| US-20230159438-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | GENZYME CORPORATION | 2023-05-25 | — | — | US | disclosed |
| US-20230147360-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | GENZYME CORPORATION | 2023-05-11 | — | — | US | disclosed |
| US-20230128062-A1 | AZABICYCLIC SUBSTITUTED OXASPIRO DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2023-04-27 | — | — | US | disclosed |
| US-20230015308-A1 | SUBSTITUTED THIAZOLE AROMATIC RING-BASED COMPOUND AND PREPARATION METHOD THEREFOR, HERBICIDAL COMPOSITION AND USE THEREOF | QINGDAO KINGAGROOT CHEMICAL COMPOUND CO., LTD. (CN) | 2023-01-19 | — | — | US | disclosed |
| WO-2022117882-A2 | NOVEL PAR-2 INHIBITORS | DOMAIN THERAPEUTICS (FR) | 2022-06-09 | — | — | WO | disclosed |
| US-20080004273-A1 | Inhibitors of protein tyrosine kinase activity | METHYLGENE, INC. (CA) | 2008-01-03 | — | — | US | disclosed |
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE, INC. | 2007-01-04 | — | — | US | disclosed |
| US-7125877-B2 | Benzimidazole derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-10-24 | — | — | US | disclosed |
| EP-1505063-A1 | BENZIMIDAZOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-02-09 | — | — | EP | disclosed |
| US-20030236267-A1 | Benzimidazole derivatives | MSD K.K. (JP) | 2003-12-25 | — | — | US | disclosed |
| EP-0731803-A4 | NOVEL FURANODIAZEPINES | MERCK & CO INC (US) | 1997-06-18 | — | — | EP | disclosed |
| EP-0731803-A1 | NOVEL FURANODIAZEPINES | MERCK & CO. INC. (US) | 1996-09-18 | — | — | EP | disclosed |
| US-5453424-A | Furanodiazepines | MERCK & CO., INC. (US) | 1995-09-26 | — | — | US | disclosed |
| WO-1995014695-A1 | NOVEL FURANODIAZEPINES | MERCK & CO., INC. (US) | 1995-06-01 | — | — | WO | disclosed |
| EP-0409418-A1 | Heterocyclic tertiary alcohols | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1991-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12460128-B2 | Organic electroluminescent materials and devices | OCIAD2, OCIAD1, ICOSLG | MLYCD 8/4885MEN1 2869/4885KMT2A 2410/4885 |
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | HGF, MET, FLT1 | MLYCD 4030/4885MEN1 3655/4885KMT2A 3391/4885 |
| US-20230128062-A1 | AZABICYCLIC SUBSTITUTED OXASPIRO DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | CYP4A11, CYP51A1, CYP4F11 | MLYCD 2525/4885MEN1 351/4885KMT2A 3586/4885 |
| US-12583878-B2 | Organic electroluminescent materials and devices | SOD1, SSB, ROS1 | MLYCD 1229/4885MEN1 4357/4885KMT2A 2517/4885 |
| US-20230147360-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | CFTR, AADAC, ARSA | MLYCD 407/4885MEN1 4477/4885KMT2A 2884/4885 |
| US-20030236267-A1 | Benzimidazole derivatives | OPRL1, GPR119, NPBWR1 | MLYCD 2462/4885MEN1 1634/4885KMT2A 3564/4885 |
| US-20230159438-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | CFTR, AADAC, ARSA | MLYCD 407/4885MEN1 4477/4885KMT2A 2884/4885 |
| US-20230015308-A1 | SUBSTITUTED THIAZOLE AROMATIC RING-BASED COMPOUND AND PREPARATION METHOD THEREFOR, HERBICIDAL COMPOSITION AND USE THEREOF | WEE1, CBR3, GLRX3 | MLYCD 1423/4885MEN1 4484/4885KMT2A 3228/4885 |
| US-20240066027-A1 | NOVEL PAR-2 INHIBITORS | F2RL1, F2R, F2RL3 | MLYCD 4027/4885MEN1 1034/4885KMT2A 2201/4885 |
| US-20080004273-A1 | Inhibitors of protein tyrosine kinase activity | HGF, ERBB2, MET | MLYCD 4000/4885MEN1 3231/4885KMT2A 2353/4885 |
| US-20250333421-A1 | PYRIDAZINES OR 1,2,4-TRIAZINES SUBSTITUTED BY SPIROCYCLIC AMINES | MEN1, MLLT1, MPL | MLYCD 627/4885MEN1 1/4885KMT2A 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.